Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC. METHODS: The open-label, phase 1, mult...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Lancet Oncol
Main Authors: Hellmann, Matthew D, Rizvi, Naiyer A, Goldman, Jonathan W, Gettinger, Scott N, Borghaei, Hossein, Brahmer, Julie R, Ready, Neal E, Gerber, David E, Chow, Laura Q, Juergens, Rosalyn A, Shepherd, Frances A, Laurie, Scott A, Geese, William J, Agrawal, Shruti, Young, Tina C, Li, Xuemei, Antonia, Scott J
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5476941/
https://ncbi.nlm.nih.gov/pubmed/27932067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30624-6
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker